<DOC>
	<DOCNO>NCT00882778</DOCNO>
	<brief_summary>This study conduct Europe North South America . The primary aim observational study evaluate frequency pattern bleed episode haemophilia patient receive preventative treatment activate recombinant human factor VII . The secondary aim evaluate patient select treatment , dose dose interval use , safety activate recombinant human factor VII use prevention . The study also aim increase understand unmet medical need clinical relevance preventative treatment haemophilia patient .</brief_summary>
	<brief_title>PROPACT : Retrospective Prophylaxis Patient Case Collection</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Haemophilia A B inhibitor Prescribed use activate recombinant human factor VII type prophylaxis duration least 30 day Prophylaxis prescribe postsurgery One coagulation disorder addition haemophilia</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>